Looking for analysis of halogenated organic compounds such as chlorinated solvents in your pharma products? With our brand new Electron Capture Detector (ECD) we’ve got just the right equipment to help!

The team at QUINTA-ANALYTICA are very pleased to announce delivery of our latest innovative piece of technology in the form of specialized selective gas chromatography detectors, allowing us to offer even greater selectivity and sensitivity to our clients and partners.

By increasing our ability to detect compounds in matrices further, our new micro-electron capture detector provides trace-level analysis of halogenated organic compounds and aromatic pollutants, and is the most sensitive ECD on the market.

Produced by Agilent Technologies, and boasting reliability combined with unprecedented sensitivity and accurate quantitation of samples containing compounds with unknown concentrations, it is able to offer detection in the ranges from femtograms to nanograms per microliter.

By bolstering our line-up in this key area, Quinta are confident in repeating the last twenty years of history by remaining a fully certified top-class services provider to the global pharmaceutical industry.

Get in touch to learn more!

Additional News

  • 17 December 2025

    PF 2026: Thank You from Quinta-Analytica

    In 2025, Quinta-Analytica continued to turn complex development challenges into tangible progress. Our PF 2026 message looks back at key milestones and thanks the partners, clients, and teams who made them possible.

  • 15 December 2025

    IVBE for locally acting drugs: insights from Conscio Science Day in Munich

    Can bioequivalence for locally acting drugs be demonstrated without a single subject in a clinical trial? Yes, if your in vitro bioequivalence (IVBE) toolkit is set up in the right way.

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.